Valirx - Amends License for VAL201 with Cancer Research Technology

Dr Suzy Dilly, CEO of Valirx, discusses the amendment of the VAL201 license which will allow ValiRx and TheoremRx Inc. to proceed to full license without further CRT involvement.

Suzanne Dilly
Chief Executive Officer

Company Events - VALIRX PLC